Breaking News, Collaborations & Alliances

Appili, Saptalis Enter Commercial Pact

Saptalis to oversee the regulatory review, manufacturing and preparation for the anticipated commercialization of ATI-1501 in the U.S.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Appili Therapeutics Inc., a biopharmaceutical company focused on anti-infective drug development, has entered into a commercialization agreement with Saptalis Pharmaceuticals LLC, a specialty pharmaceuticals company, for ATI-1501, Appili’s liquid suspension reformulation of the antibiotic metronidazole. Appili is eligible to receive multiple milestone and royalty payments on the sale of ATI-1501 in the U.S. Saptalis will be responsible for overseeing the regulatory review, manufacturing and prep...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters